BMS (BMY) and NVIDIA (NVDA) Build Vera Rubin Supercomputer, Expanding AI-Driven Drug R&D Infrastructure
Major Transformation and Expansion of Bio R&D Infrastructure
Global pharmaceutical giant Bristol Myers Squibb (BMS, BMY) has announced a significant expansion of its collaboration with NVIDIA (NVDA) to build one of the largest single computing infrastructures in the life sciences. The companies plan to significantly expand their NVIDIA DGX SuperPOD infrastructure, which was initially implemented three years ago, with the next-generation Vera Rubin NVL72 system, creating a state-of-the-art AI Factory. This move, which goes beyond a simple technology demonstration, aims to internalize independent, high-performance supercomputing capabilities, driven by the strategic need to simulate vast omics data and molecular structures in real-time. As a result, BMS will have a powerful computing foundation that allows it to execute large-scale AI models from the early stages of drug discovery.
Hybrid Intelligence-Based R&D Efficiency Innovation
The core value of this initiative lies in the implementation of a hybrid intelligence model, where researchers and AI work together synergistically. According to Robert Plenge, BMS Chief Scientific Officer (CRO), the ultimate goal is not only to improve experimental speed but also to increase the overall probability of success (PoS) in the development pipeline. By actively applying AI virtual simulations, from small molecule simulations to protein engineering and target discovery, the company aims to create an environment where researchers can focus on high-level decision-making rather than manual tasks. This is expected to be a pivotal step in transforming the traditional wet-lab-centric R&D structure into a data science-driven dry-lab hybrid structure.
Building a Comprehensive AI Ecosystem and Strategic Synergy
In addition to the introduction of NVIDIA hardware, BMS has been building a multi-AI ecosystem by diversifying the adoption of Anthropic's Claude platform and Microsoft's diagnostic algorithm network. Greg Meyers, Chief Digital Technology Officer (CDTO), explains that this investment is part of a comprehensive, mutually complementary AI strategy, and that tangible results are already being seen in the R&D pipeline and operational efficiency. By combining Claude for biological mechanism analysis with NVIDIA's ultra-fast GPU infrastructure for large-scale structural computing and molecular modeling, the company is maximizing synergy. Ultimately, the goal is to reduce the failure rate in late-stage clinical trials for key pipeline products such as cancer drugs and autoimmune disease treatments, creating a virtuous cycle that reduces massive development costs.
Competition for Computing Leadership Among Big Pharma and Reshaping of the Industry
The global pharmaceutical industry is currently engaged in intense competition to secure ultra-large computing resources, centered around NVIDIA partnerships. Similar to Eli Lilly (LLY), which established a joint innovation lab with NVIDIA with a $1 billion investment over five years, and Roche (RHHBY), which announced a hybrid cloud AI factory, BMS is also responding by building its own independent infrastructure. As computing power for molecular data becomes a key asset in gaining pipeline advantages, the AI gap between big pharma companies is directly linked to differences in technology and drug launch speed. As a result, this bold investment in facilities is expected to be a decisive turning point in solidifying BMS's leading position in the healthcare big data market.
With the global AI-driven drug development market expected to grow at an annual rate of over 25% to exceed $5 billion by 2030, BMS's (BMY) introduction of the NVIDIA Vera Rubin supercomputer will have a significant short-term impact, reducing the R&D timeline from initial target discovery to the pre-clinical stage by up to 30-50%. In the medium to long term, it is expected to significantly improve R&D ROI by proactively reducing the risk of attrition in Phase 3 clinical trials, which cost billions of dollars annually, through candidate optimization. This will enable BMS to narrow the technology gap with competing big pharma companies such as Eli Lilly (LLY), which has invested $1 billion over five years to establish a joint AI lab, and Roche (RHHBY), which has positioned AI factories as a key strategy, and gain an advantage in the race to secure drug pipelines. From a capital market perspective, by internalizing independent, high-performance computing assets rather than simply licensing software, this will serve as a key catalyst for re-evaluating the value of BMY's autoimmune and anti-cancer drug pipelines.
Source: FierceBiotech (rss)